

ChromoGenics

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

ChromoGenics' rights issue of approximately MSEK 40 is guaranteed to approximately 80%, corresponding to approximately 33 MSEK

Through guarantee and subscription commitments, ChromoGenics AB (publ) has secured approximately 80% of the rights issue of approximately MSEK 40 with a planned subscription period of 8-22 January 2018.

In order to support ChromoGenics' strategic initiatives, the Board decided on November 16, 2017, subject to the subsequent approval of the Extraordinary General Meeting (EGM) to issue a rights issue. The issue decision was approved by the EGM on December 15, 2017.

The rights issue will strengthen the Company's balance sheet and secures continued market expansion and necessary investments in the production process, for better cost efficiency and profitability.

Subscription commitments of approximately MSEK 1 and guarantee commitments of approximately MSEK 32 have been concluded, which corresponds to approximately 80% of the maximum amount of the rights issue, which at full subscription amounts to approximately 40.6 MSEK before issue costs.

Complete terms and conditions for the Rights Issue and other information about the Company will be disclosed in the prospectus which will be published before the start of the subscription period.

Indicative timetable

4 January 2018	Record date for the right to participate in the Rights Issue
8 – 22 January 2018	Subscription period
8 – 18 January 2018	Trade with unit rights
About 26 January 2018	Announcement of preliminary outcome of the Rights Issue

Financial and legal advisors regarding the Rights Issue

Evli Bank Plc. is financial advisor and Advokatfirman Lindahl KB is legal advisor to ChromoGenics in connection with the issue.

For more information, please contact

Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
+46 (0)18 430 04 30
info@chromogenics.com
Certified Adviser: G&W Fondkommission

This information constitutes such information that ChromoGenics AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted by the above-mentioned contact persons for publication on 3 January 2018, at 8:30 a.m. CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

IMPORTANT INFORMATION

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in ChromoGenics. Any invitation to the persons concerned to subscribe for shares in ChromoGenics will only be made through the prospectus referred to in this press release.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to those required under Swedish laws and regulations. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No shares have been or will be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), or securities legislation in any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect ChromoGenics's current view on future events and financial and operational development. The words "intend", "estimate", "expect", "may", "plan", "anticipate" or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although ChromoGenics believes that these statements are based on reasonable assumptions and expectations, ChromoGenics cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties, and the outcome could differ materially from the information set out in the forward-looking statements.

About ChromoGenics

ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company's unique electrochromic technology ConverLight® provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.

www.chromogenics.com